This diagnostic agent called PYLARIFY (piflufolastat F 18) is given to patients as an injection. Once it is in the body, it binds to PSMA, or Prostate-Specific Membrane Antigens. Prostate cancer cells usually have a higher level of PSMA.
While standard scans have limited sensitivity for prostate cancer, this advanced imaging using PYLARIFY and PET scans is much more capable of identifying prostate cancer, giving physicians a clearer image of prostate cancer lesions and allowing them to determine if the cancer is limited to the prostate or if it has spread to other parts of the body.
â€œIt allows us to make sure weâ€™re not missing any sites of cancer that arenâ€™t picked up with old-school imaging,â€ said Wellstar UrologistÂ Dr. Justin Watson. â€œIf there is an area of cancer outside what weâ€™d typically treat and we pick it up with this imaging, we can make sure we address that area, too.â€
Providers can then move forward with the best course of action, tailor treatment to each patientâ€™s individual needs, and collaborate with the patient to improve outcomes.
Wellstar Radiation OncologistÂ Dr. Justin HartÂ and Dr. Watson compared the new imaging technology to upgrading a 20 inch tube-style TV from 1981 to a 60 inch LCD flat-screen TV today.
â€œThis is several leaps forward in our ability to see prostate cancer on a scan in high resolution,â€ Dr. Watson said. â€œIn the older scans, things are difficult to see and sometimes not even perceptible, and with the new scans, they light right up and we know much better what weâ€™re dealing with.â€
This PSMA imaging is currently available atÂ Wellstar Kennestone Hospital, with plans to expand to other locations.